hydroxychloroquine has been researched along with Sleep Apnea Syndromes in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Sleep Apnea Syndromes: Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxychloroquine (HCQ) is an immunomodulator used to treat rheumatoid arthritis and systemic lupus erythematosus." | 5.41 | Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial. ( Boll, L; Cadaval Gonçalves, S; Cortes, A; Eibel, B; Irigoyen, MC; Martinez, D; Rossi, B; Tedesco Silva, LM; Waclawovsky, G, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tedesco Silva, LM | 1 |
| Cortes, A | 1 |
| Rossi, B | 1 |
| Boll, L | 1 |
| Waclawovsky, G | 1 |
| Eibel, B | 1 |
| Cadaval Gonçalves, S | 1 |
| Irigoyen, MC | 1 |
| Martinez, D | 1 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial[NCT04161339] | Phase 4 | 50 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxychloroquine and Sleep Apnea Syndromes
| Article | Year |
|---|---|
Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial.
Topics: Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
1 other study available for hydroxychloroquine and Sleep Apnea Syndromes
| Article | Year |
|---|---|
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |